The complexity of testing and treatment for lung cancer patients will only increase as additional mutations and therapies are identified. In order to provide optimal patient care in this rapidly changing landscape, it is crucial to develop reliable processes now for performing, reporting and utilizing molecular testing in patients with lung cancer. With the broad aims of improving care for lung cancer patients in Florida and building a solid foundation for molecular testing in the future, the specific aims of this project are to:
1. Evaluate current practices and barriers to lung cancer molecular testing in the state of Florida; and
2. Develop sustainable and comprehensive practices through the Florida Initiative for Quality Cancer Care (FIQCC) network to ensure access to molecular testing and appropriate targeted therapy for patients with advanced lung cancer.